“Looking ahead to 2011, while some uncertainty has been removed with the national reimbursement rate, we will not be providing financial guidance until we reach a period of greater predictability. Our objective for 2011 is to organically grow patient volume in our core cardiac monitoring business through the disciplined execution of our sales plan. Additionally, we will continue to evaluate external opportunities that will augment this growth or provide complementary products and services. We will execute the full commercial launch of our next generation MCOT TM system, C5, which has enhanced features and a lower cost of sales. With $45 million of cash and investments and a strong operational foundation, I am confident we will execute on this plan.”Fourth Quarter Financial Results
CardioNet, Inc. Reports Fourth Quarter And Full Year 2010 Financial Results
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.